Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 10.3 Cr.
- Current Price ₹ 4.14
- High / Low ₹ 26.2 / 2.97
- Stock P/E
- Book Value ₹ 16.9
- Dividend Yield 0.00 %
- ROCE -5.83 %
- ROE -14.3 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.25 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -11.6% over past five years.
- Promoter holding is low: 27.1%
- Company has a low return on equity of -3.43% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 34.5% of their holding.
- Company has high debtors of 184 days.
- Promoter holding has decreased over last 3 years: -39.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
23 | 31 | 47 | 52 | 66 | 62 | 57 | 72 | 64 | 68 | 59 | 31 | |
19 | 26 | 39 | 42 | 53 | 55 | 49 | 63 | 59 | 58 | 51 | 34 | |
Operating Profit | 4 | 5 | 8 | 10 | 13 | 8 | 8 | 10 | 5 | 9 | 8 | -3 |
OPM % | 16% | 16% | 16% | 20% | 20% | 13% | 14% | 13% | 8% | 13% | 13% | -10% |
0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -12 | |
Interest | 1 | 1 | 4 | 5 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 2 |
Depreciation | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 3 |
Profit before tax | 2 | 3 | 2 | 3 | 5 | 1 | 0 | 1 | -2 | 1 | 0 | -20 |
Tax % | 32% | 32% | 29% | 25% | 24% | 31% | 188% | 51% | -4% | 10% | -3,800% | -0% |
2 | 2 | 2 | 2 | 4 | 1 | -0 | 0 | -2 | 1 | 0 | -20 | |
EPS in Rs | 154.00 | 186.00 | 110.71 | 165.00 | 285.71 | 0.38 | -0.03 | 0.14 | -0.91 | 0.43 | 0.16 | -7.87 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -12% |
3 Years: | -22% |
TTM: | -47% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2003% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -24% |
3 Years: | -39% |
1 Year: | -83% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -3% |
3 Years: | -3% |
Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 1 | 1 | 1 | 1 | 17 | 23 | 23 | 25 | 25 | 25 | 25 |
Reserves | 5 | 7 | 10 | 12 | 16 | 5 | 36 | 37 | 35 | 36 | 37 | 17 |
16 | 32 | 31 | 40 | 50 | 49 | 51 | 49 | 43 | 43 | 41 | 40 | |
4 | 6 | 15 | 8 | 8 | 22 | 24 | 25 | 36 | 36 | 40 | 61 | |
Total Liabilities | 26 | 46 | 57 | 61 | 77 | 92 | 135 | 135 | 140 | 141 | 143 | 143 |
2 | 19 | 18 | 21 | 20 | 23 | 21 | 19 | 33 | 29 | 26 | 23 | |
CWIP | 10 | 5 | 5 | 4 | 7 | 6 | 25 | 26 | 13 | 14 | 15 | 15 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 7 | 7 | 7 | 7 |
14 | 22 | 33 | 36 | 50 | 62 | 82 | 83 | 87 | 90 | 95 | 97 | |
Total Assets | 26 | 46 | 57 | 61 | 77 | 92 | 135 | 135 | 140 | 141 | 143 | 143 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 10 | 6 | 8 | 13 | -9 | 5 | 6 | 2 | 7 | 21 | |
0 | 0 | -5 | -4 | -3 | -8 | -25 | -1 | -4 | -1 | -1 | -0 | |
0 | 0 | -5 | -2 | -6 | -3 | 35 | -5 | -3 | -1 | -6 | -3 | |
Net Cash Flow | 0 | 0 | 0 | 0 | -0 | 2 | 1 | -1 | -1 | -0 | -0 | 17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 121 | 116 | 95 | 97 | 142 | 130 | 128 | 93 | 104 | 127 | 114 | 184 |
Inventory Days | 169 | 159 | 137 | 128 | 160 | 144 | 267 | 260 | 325 | 310 | 404 | 461 |
Days Payable | 60 | 71 | 122 | 21 | 53 | 144 | 217 | 179 | 275 | 211 | 270 | 609 |
Cash Conversion Cycle | 230 | 204 | 111 | 204 | 249 | 130 | 178 | 175 | 154 | 227 | 248 | 35 |
Working Capital Days | 159 | 165 | 108 | 165 | 199 | 158 | 142 | 121 | 192 | 210 | 209 | -102 |
ROCE % | 20% | 14% | 15% | 17% | 18% | 9% | 7% | 7% | 3% | 6% | 5% | -6% |
Documents
Announcements
- Financial Results For Year Ended 31/03/2025 23h
-
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
5 Jun - Cian Healthcare's CIRP Resolution Plan considered by NCLT on June 5; next hearing July 1, 2025.
-
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
30 May - Delay in audited financial results due to CIRP of company and subsidiary, impacting statutory compliance timelines.
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
28 May - 12th Committee of Creditors meeting scheduled for May 29, 2025, in Cian Healthcare's CIRP process.
-
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
24 May - Arbitration stay granted amid ongoing insolvency resolution process at Cian Healthcare.
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.